keyword
MENU ▼
Read by QxMD icon Read
search

Non hodgkins lymphoma

keyword
https://www.readbyqxmd.com/read/28443591/clinical-findings-of-pediatric-hiv-infection-at-a-tertiary-center-in-turkey
#1
Murat Sütçü, Manolya Acar, Hacer Aktürk, Selda Hançerli Torun, Hayati Beka, Ali Ağaçfidan, Nuran Salman, Ayper Somer
BACKGROUND: Pediatric HIV infection is different from adult type of disease in many ways including transmission routes, clinical findings and treatment strategies. AIMS: Our aim was to evaluate clinical data of our pediatric HIV patients. STUDY DESIGN: Retrospective cross-sectional study. METHODS: The charts of 22 pediatric patients diagnosed with HIV infection in our clinic during a 14 year period through 2001-2015 were retrospectively analyzed...
April 6, 2017: Balkan Medical Journal
https://www.readbyqxmd.com/read/28441249/epidemiology-of-second-primary-tumors-in-women-with-ovarian-cancer
#2
Tomi T Kanninen, Dimitrios Nasioudis, Giovanni Sisti, Kevin Holcomb, Mariarosaria Di Tommaso, Susan Khalil, Anar Gojayev, Steven S Witkin
OBJECTIVE: The last large study of second primary tumors (SPTs) in women with ovarian cancer was published in 1996, prior to major changes in the differential diagnosis and treatment. The present study reports on the incidence of SPTs in a contemporary cohort of patients with a diagnosis of ovarian cancer. METHODS: Ovarian cancer patients with a diagnosis of an ovarian malignancy between 1992 and 2012 were identified and characterized from 13 registries of the Surveillance, Epidemiology, and End Results database...
May 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28440948/novel-reduction-sensitive-micellar-nanoparticles-assembled-from-rituximab-doxorubicin-conjugates-as-smart-and-intuitive-drug-delivery-systems-for-the-treatment-of-non-hodgkin-s-lymphoma
#3
Huabin Yin, Tong Meng, Ling Shu, Min Mao, Lei Zhou, Haiyan Chen, Dianwen Song
In this study, a novel reduction-sensitive drug delivery system, the Rituximab-Doxorubicin (RTX-DOX) micellar nanoparticle (RDMN), was specially designed for targeted delivery and release of DOX in Non-Hodgkin's Lymphoma (NHL) cells. The RDMN was fabricated by self-assembling of amphiphilic RTX-DOX conjugates (RDCs), which were synthesized by conjugating the hydrophilic Fab fragments of RTX (an anti-CD20 monoclonal antibody) and hydrophobic DOXs by a reduction-responsive linker, 3-(2-Pyridyldithio) propionyl hydrazide (PDPH)...
April 25, 2017: Chemical Biology & Drug Design
https://www.readbyqxmd.com/read/28440608/association-of-human-cytomegalovirus-with-hodgkin%C3%A2-s-disease-and-non-hodgkin%C3%A2-s-lymphomas
#4
Hamide Mehravaran, Manoochehr Makvandi, Alireza Samarbaf Zade, Niloofar Neisi, Hadis Kiani, Hashem Radmehr, Toran Shahani, Seyedeh Zeinab Hoseini, Nastaran Ranjbari, Rahil Nahid Samiei
Background and Objective: The human cytomegalovirus (HCMV) can persist lifelong as a latent infection and may result in a series of disorders. Associations with both Hodgkin’s disease and non-Hodgkin´s lymphomas have been reported. Expression of the unique long (UL)138 gene of HCMV is linked with the viral latency phase while that of the immediate-early (IE)1 gene is typical of the viral replication phase in patients. This study conducted to determine the prevalence of CMV latent infection in histological tissue samples from patients with Hodgkin’s and Non-Hodgkin´s lymphomas...
March 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28439761/small-molecule-inhibitors-in-chronic-lymphocytic-lymphoma-and-b-cell-non-hodgkin-lymphoma
#5
REVIEW
Allison Rosenthal
PURPOSE OF REVIEW: The purpose of this review is to summarize the available literature for the use of small molecule inhibitors in chronic lymphocytic leukemia and B cell non-Hodgkin lymphoma. RECENT FINDINGS: Ibrutinib, idelalisib, and venetoclax are small molecule inhibitors that have revolutionized therapeutic options for patients with CLL, particularly for those with high-risk disease including 17p deletion. These drugs are increasingly finding application in a variety of subtypes of B cell NHL...
April 24, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28438082/radioimmunoconjugates-for-treating-cancer-recent-advances-and-current-opportunities
#6
Mickaël Bourgeois, Clément Bailly, Mathieu Frindel, François Guerard, Michel Chérel, Alain Faivre-Chauvet, Françoise Kraeber-Bodéré, Caroline Bodet-Milin
Radioimmunoconjugates have been used for 30 years to diagnose and treat cancer. For many years, the use of these therapeutic tools has been limited to haematological disorders, such as non-Hodgkin's lymphoma, given that they have only had a moderate effect on solid tumours. Areas covered: Recently, several strategies have revived the potential therapeutic application for radioimmunoconjugates. In this review, the authors review the advances in immunological engineering to develop new tools like monoclonal antibodies and their derivatives...
April 24, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28436299/mgmt-gene-variants-temozolomide-myelotoxicity-and-glioma-risk-a-concise-literature-survey-including-an-illustrative-case
#7
Meric A Altinoz, Ilhan Elmaci, Fatih Han Bolukbasi, Cumhur Gokhan Ekmekci, Guven Yenmis, Ramazan Sari, Aydin Sav
Temozolomide may cause thrombocytopenia or neutropenia in 3-4% of glioblastoma patients, respectively. However, pancytopenia is rarely reported. MGMT (O6-methylguanine-DNA-methyltransferase) enzyme repairs temozolomide-induced DNA mutations and associates both with antitumour efficacy and myelosuppression. Many studies on the effects of MGMT gene-methylation on temozolomide's effects exist, but much fewer publications concerning MGMT variants were documented. A full sequencing of the MGMT gene was performed in a female glioblastoma patient, who developed pancytopenia following temozolomide treatment...
April 23, 2017: Journal of Chemotherapy
https://www.readbyqxmd.com/read/28435836/the-comparative-diagnostic-features-of-canine-and-human-lymphoma
#8
Davis M Seelig, Anne C Avery, E J Ehrhart, Michael A Linden
The non-Hodgkin lymphomas (NHLs) are a heterogeneous family of lymphoid malignancies that are among the most common neoplasms of both dogs and humans. Owing to shared molecular, signaling, incidence, and pathologic features, there is a strong framework supporting the utilization of canine lymphoma as a comparative, large animal model of human NHL. In alignment with the biologic similarities, the current approach towards the diagnosis and classification of canine lymphoma is based upon the human World Health Organization guidelines...
June 2016: Veterinary Sciences
https://www.readbyqxmd.com/read/28435401/head-and-neck-lymphomas-a-retrospective-ten-year-observation
#9
Marcelina Niemiec, Grażyna Stryjewska-Makuch, Małgorzata Janik, Bogdan Kolebacz, Grażyna Lisowska, Wojciech Ścierski
AIM OF THE STUDY: Lymphomas are a heterogeneous group of tumours of lymphoid tissue in which there is an abnormal proliferation of cells of the lymphatic system. The literature notes a gradual increase in the incidence of this type of cancer in the whole population. The aim of the study was to evaluate whether the above tendency occurs in the head and neck area. MATERIAL AND METHODS: In the years 2005-2014, at the Otolaryngology and Laryngological Oncology Department of the Upper Silesian Medical Centre in Katowice, 77 cases of lymphoma were recorded, 58 of which were analysed in terms of location, histological type, age and sex of the patient, and the presence of risk factors...
2017: Contemporary Oncology Współczesna Onkologia
https://www.readbyqxmd.com/read/28434095/patient-reported-outcomes-in-cancer-survivors-a-population-wide-cross-sectional-study
#10
Michael Jefford, Andrew C Ward, Karolina Lisy, Karen Lacey, Jon D Emery, Adam W Glaser, Hannah Cross, Mei Krishnasamy, Sue-Anne McLachlan, Jim Bishop
PURPOSE: There is a lack of robust population-based data regarding the lived experience of cancer survivors. This study assessed the quality of life (QoL) of survivors of breast, colorectal, or prostate cancer, non-Hodgkin lymphoma or melanoma 1, 3 and 5 years post-diagnosis. Associations between various demographic and disease-related factors and QoL were assessed. METHODS: A cross-sectional postal survey was undertaken. Eligible participants were identified from a population-based cancer registry...
April 22, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28430788/time-and-spatial-trends-in-lymphoid-leukemia-and-lymphoma-incidence-and-survival-among-children-and-adolescents-in-manitoba-canada-1984-2013
#11
Xibiao Ye, Mahmoud Torabi, Lisa M Lix, Salaheddin M Mahmud
OBJECTIVES: To test for time and spatial trends in lymphoid malignancies, including lymphoid leukemia (LL), Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL), in children and adolescents in the province of Manitoba, Canada. METHODS: Incident cases diagnosed between 1984 and 2013 were identified from the Manitoba Cancer Registry. We assessed time trends in age-standardized incidence rates using joinpoint regression and in 5-year relative survival using Poisson regression model...
2017: PloS One
https://www.readbyqxmd.com/read/28430651/doxorubicin-loaded-platelets-conjugated-with-anti-cd22-mabs-a-novel-targeted-delivery-system-for-lymphoma-treatment-with-cardiopulmonary-avoidance
#12
Peipei Xu, Huaqin Zuo, Rongfu Zhou, Fan Wang, Xu Liu, Jian Ouyang, Bing Chen
B-cell lymphoma accounts for approximately 85% of all adult non-Hodgkin's lymphoma cases. Doxorubicin (DOX) is an indispensable drug for the treatment of non-Hodgkin's lymphoma. However, DOX causes severe cardiotoxicity, which limits its use in conventional treatment strategies. In this study, we developed a novel drug delivery system for lymphoma treatment: DOX-loaded platelets that were conjugated with anti-CD22 monoclonal antibodies (mAbs) (DOX-platelet-CD22). Platelets are bio- and immune-compatible drug carriers that can prolong the circulation time of drugs...
April 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/28430351/c677t-and-a1298c-polymorphisms-of-methylene-tetrahydrofolate-reductase-in-non-hodgkin-lymphoma-southeast-iran
#13
Mohammad Ali Mashhadi, Ebrahim Miri-Moghaddam, Narges Arbabi, Ali Bazi, Zahra Heidari, Zahra Sepehri, Azra Karimkoshte, Alireza Rezvan, Seyed Mahdi Hashemi
PURPOSE: Polymorphisms of the methylene tetrahydrofolate reductase (MTHFR) gene have been reported as risk factors for non-Hodgkin lymphoma (NHL) in some populations. Our goal was to evaluate the potential role of A1298C and C677T polymorphisms of MTHFR in risk of NHL in southeast Iran. METHODS: In the present case-control study, 127 patients with newly diagnosed NHL along with 150 ethnicity- and age-matched controls were examined. The A1298C and C677T polymorphisms were genotyped using the Tetra Amplification Refractory Mutation System polymerase chain reaction method...
April 14, 2017: Tumori
https://www.readbyqxmd.com/read/28430171/the-prognostic-value-of-18-fdg-positron-emission-tomography-in-t-cell-non-hodgkin-lymphoma
#14
R Eslick, L Dunlop, M Lin, D Hsu, S Ling
No abstract text is available yet for this article.
April 21, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28428903/sle-and-non-hodgkin-s-lymphoma-a-case-series-and-review-of-the-literature
#15
Prajwal Boddu, Abdul S Mohammed, Chandrahasa Annem, Winston Sequeira
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder punctuated by varied multiorgan complications all along the course of its natural history. Lymphoma represents a relatively well-recognized malignant phenomenon associated with lupus. The cause and effect relationships of lymphoma in SLE have been subject to extensive scrutiny with several studies reporting on clinic-pathologic characteristics and risk factors predicting lymphoma development in SLE. However, the pathogenic role of immunosuppressives in SLE-related lymphoma still remains unclear, and indices to help guide diagnosis, prognostication, therapy, and posttreatment monitoring are yet to be established...
2017: Case Reports in Rheumatology
https://www.readbyqxmd.com/read/28428095/sjogren-s-syndrome-clinical-aspects
#16
Frederick B Vivino
Sjogren's syndrome (SS) is the 2nd most common chronic autoimmune rheumatic disease and associated with a high burden of illness. Morbidity arises not only from untreated xerostomia and keratoconjunctivitis sicca but also from extra-glandular manifestations and the development of non-Hodgkin's B cell lymphomas. Proper diagnosis of SS requires objective evidence of dry eyes and/or objective evidence of dry mouth and proof of autoimmunity. The recent development of new international classification criteria and clinical practice guidelines for SS should not only enhance the existing standards of care but also facilitate further studies to improve future diagnosis and management...
April 17, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/28427693/a-case-of-cd30-alk1-anaplastic-large-cell-lymphoma-resembling-acute-disseminated-encephalomyelitis
#17
T Afrantou, K S Natsis, G Papadopoulos, R Lagoudaki, C Poulios, D Mamouli, I Kostopoulos, N Grigoriadis
Central nervous system involvement is an uncommon complication of systemic non-Hodgkin lymphomas. The majority of these cases concern B-cell lymphomas. We report a case of systemic T-cell anaplastic large cell lymphoma CD30+ ALK- with CNS involvement at the time of diagnosis and unusual MRI characteristics resembling acute disseminated encephalomyelitis.
April 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28427526/potential-application-and-prevalence-of-the-cd30-ki-1-antigen-among-solid-tumors-a-focus-review-of-the-literature
#18
REVIEW
Garrett K Berger, Kevin Gee, Cassandra Votruba, Ali McBride, Faiz Anwer
BACKGROUND: CD30 (Ki-1) is a cell membrane protein derived from the tumor necrosis factor (TNF) receptor family. The CD30 antigen has been associated primarily with Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Brentuximab vedotin (BV) is an antibody-drug conjugate targeting the CD30 antigen. FDA approval for BV includes relapsed and refractory HL and sALCL. The CD30 antigen also has been identified in many solid tumors, predominantly of germ cell origins and early clinical data is promising...
May 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28427281/the-servier-oncology-pipeline-in-2017
#19
Patrick Therasse, Beatrice Perron, Sarah A Novack, Jean-Pierre Abastado
Cancer is a complex, multifactorial disease that for years has been the focus of intensive research efforts to explore both the molecular and biological mechanisms involved and the development of novel agents to target these pathways. Servier is an independent French pharmaceutical company with a focus on oncology. Currently, Servier's commercial portfolio includes agents used to treat non-Hodgkin's lymphoma and metastatic colorectal cancer; Servier's oncology pipeline involves agents for the treatment of both solid and hematological tumors...
April 21, 2017: Future Oncology
https://www.readbyqxmd.com/read/28427218/methotrexate-plus-idarubicin-improves-outcome-of-patients-with-primary-central-nervous-system-lymphoma
#20
Ni Fan, Lu Zhang, Xiaoping Xu, Bobin Chen, Chen Zhu, Pei Li, Zi Chen, Tianling Ding, Yan Ma, Yan Yuan, Zhiguang Lin
Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma with poor long-term survival. This study assessed methotrexate (MTX) plus idarubicin (IDA) in treating patients of PCNSL comparing to MTX alone therapy. A total of 100 patients were retrospectively enrolled and subjected to MTX alone (n = 52) and MTX plus IDA (n = 48). The completed response (CR) rate in patients treated with MTX plus IDA was 62.50%, and overall response (OR) rate was 79.17%, which in MTX alone cohort were 42...
March 4, 2017: Oncotarget
keyword
keyword
12280
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"